<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032704</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-005</org_study_id>
    <nct_id>NCT04032704</nct_id>
  </id_info>
  <brief_title>A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors</brief_title>
  <official_title>Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different&#xD;
      types of solid tumors. It will also find out what side effects may occur. A side effect is&#xD;
      anything the drug does besides treating cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to assess the antitumor activity, safety, and tolerability of LV for&#xD;
      the treatment of solid tumors. Participants with the following advanced solid tumors will be&#xD;
      enrolled:&#xD;
&#xD;
      Cohort 1: small cell lung cancer (SCLC) Cohort 2: non-small cell lung cancer-squamous&#xD;
      (NSCLC-squamous) Cohort 3: non-small cell lung cancer-nonsquamous (NSCLC-nonsquamous) Cohort&#xD;
      4: head and neck squamous cell carcinoma (HNSCC) Cohort 5: esophageal squamous cell carcinoma&#xD;
      (esophageal-squamous) Cohort 6: gastric and gastroesophageal junction (GEJ) adenocarcinoma&#xD;
      Cohort 7: castration-resistant prostate cancer (CRPC) Cohort 8: melanoma&#xD;
&#xD;
      Participants will continue to receive study treatment until disease progression, unacceptable&#xD;
      toxicity, investigator decision, consent withdrawal, study termination by the sponsor,&#xD;
      pregnancy, or death, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (ORR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Confirmed ORR is defined as the proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate-specific antigen (PSA) response rate as determined by investigator according to Prostate Cancer Clinical Trials Working Group 3 criteria (Cohort 7 only)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Confirmed PSA response rate is defined as the proportion of participants with a reduction from baseline PSA level of at leat 50%, measured twice â‰¥3 weeks apart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>DCR is defined as the proportion of participants who achieve a confirmed CR or PR, or meet the stable disease (SD) criteria at least once after start of study treatment at a minimum interval of 5 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-DOR as determined by investigator assessment (Cohort 7 only)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>PSA-DOR is defined as the time from the first documentation of PSA response to the first documentation of PSA progression or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA-PFS as determined by investigator assessment (Cohort 7 only)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>PSA-PFS is defined as the time from the start of study treatment to first occurrence of PSA progression or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>OS is defined as the time from the start of study treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Pharmacokinetic (PK) endpoint of LV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>PK endpoint of LV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATAs) to LV</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer, Squamous</condition>
  <condition>Non-small Cell Lung Cancer, Non-squamous</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Ladiratuzumab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-LIV1A monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ladiratuzumab vedotin</intervention_name>
    <description>Intravenous (into the vein; IV) infusion</description>
    <arm_group_label>Ladiratuzumab Vedotin</arm_group_label>
    <other_name>SGN-LIV1A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  All Cohorts&#xD;
&#xD;
               -  Measurable disease according to RECIST v1.1 as assessed by the investigator&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1&#xD;
&#xD;
          -  Cohort 1: SCLC&#xD;
&#xD;
               -  Must have extensive stage disease&#xD;
&#xD;
               -  Must have disease progression during or following prior platinum-based systemic&#xD;
                  chemotherapy for extensive stage disease;&#xD;
&#xD;
               -  No more than 1 prior line of cytotoxic chemotherapy for extensive disease stage&#xD;
&#xD;
               -  No more than 1 prior line of cytotoxic chemotherapy for extensive disease stage&#xD;
&#xD;
               -  May have received prior anti-PD(L)1 therapy&#xD;
&#xD;
          -  Cohort 2: NSCLC-squamous&#xD;
&#xD;
               -  Must have unresectable locally advanced or metastatic disease&#xD;
&#xD;
               -  Must have disease progression during or following systemic therapy&#xD;
&#xD;
                    -  Participants must have progressed during or after a platinum-based&#xD;
                       combination therapy administered for the treatment of metastatic disease, OR&#xD;
&#xD;
                    -  Participants must have progressed within 6 months of last dose of&#xD;
                       platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or&#xD;
                       concomitant chemoradiation regimen for early stage or locally advanced stage&#xD;
                       disease.&#xD;
&#xD;
               -  Participants with known epidermal growth factor receptor (EGFR), anaplastic&#xD;
                  lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable&#xD;
                  mutations are not eligible&#xD;
&#xD;
               -  No more than 1 prior line of cytotoxic chemotherapy for their advanced disease&#xD;
&#xD;
               -  Must have received prior anti-PD(L)1 therapy, unless contraindicated&#xD;
&#xD;
          -  Cohort 3: NSCLC-nonsquamous&#xD;
&#xD;
               -  Must have unresectable locally advanced or metastatic disease&#xD;
&#xD;
               -  Must have disease progression during or following systemic therapy&#xD;
&#xD;
                    -  Participants must have progressed during or after a platinum-based&#xD;
                       combination therapy administered for the treatment of metastatic disease, OR&#xD;
&#xD;
                    -  Participants must have progressed within 6 months of last dose of&#xD;
                       platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or&#xD;
                       concomitant chemoradiation regimen for early stage or locally advanced state&#xD;
                       disease.&#xD;
&#xD;
               -  Participants with known EGFR, ALK, ROS, BRAF, tropomyosin receptor kinase (TRK),&#xD;
                  or other actionable mutations are not eligible&#xD;
&#xD;
               -  Must have had prior platinum-based chemotherapy&#xD;
&#xD;
               -  No more than 1 prior line of cytotoxic chemotherapy for their advanced disease&#xD;
&#xD;
               -  Must have received prior anti-PD(L)1 therapy, unless contraindicated&#xD;
&#xD;
          -  Cohort 4: HNSCC&#xD;
&#xD;
               -  Must have unresectable locally recurrent or metastatic disease&#xD;
&#xD;
                    -  Must have disease progression during or following prior line of systemic&#xD;
                       therapy&#xD;
&#xD;
                    -  Disease progression after treatment with a platinum-containing regimen for&#xD;
                       recurrent/metastatic disease; or&#xD;
&#xD;
                    -  Recurrence/progression within 6 months of last dose of platinum therapy&#xD;
                       given as part of a multimodal therapy in the curative setting&#xD;
&#xD;
               -  No more than 1 line of cytotoxic chemotherapy for their advanced disease&#xD;
&#xD;
               -  May have received prior anti-PD(L)1 therapy, unless contraindicated&#xD;
&#xD;
          -  Cohort 5: esophageal-squamous&#xD;
&#xD;
               -  Must have unresectable locally advanced or metastatic disease&#xD;
&#xD;
               -  Must have disease progression during or following systemic therapy&#xD;
&#xD;
               -  Must have had prior platinum-based chemotherapy&#xD;
&#xD;
               -  No more than 1 line of cytotoxic chemotherapy for their advanced disease&#xD;
&#xD;
          -  Cohort 6: gastric and GEJ adenocarcinoma&#xD;
&#xD;
               -  Must have unresectable locally advanced or metastatic disease&#xD;
&#xD;
               -  Must have received prior platinum-based therapy&#xD;
&#xD;
               -  Must have disease progression during or following systemic therapy&#xD;
&#xD;
               -  Participants with known human epidermal growth factor receptor 2 (HER2)&#xD;
                  overexpression must have received prior HER2-targeted therapy&#xD;
&#xD;
               -  No more than 1 line of prior cytotoxic chemotherapy for their advanced disease&#xD;
&#xD;
               -  Participants may have received prior anti-PD(L)1 therapy, unless contraindicated&#xD;
&#xD;
          -  Cohort 7: CRPC&#xD;
&#xD;
               -  Must have histologically or cytologically confirmed adenocarcinoma of the&#xD;
                  prostate&#xD;
&#xD;
                    -  Participants with components of small cell of neuroendocrine histology are&#xD;
                       excluded&#xD;
&#xD;
               -  Must have metastatic castration-resistant disease&#xD;
&#xD;
               -  Must have been â‰¥28 days between cessation of androgen receptor-targeted therapy&#xD;
                  and start of study treatment&#xD;
&#xD;
               -  Must have received no more than 1 prior line of androgen receptor-targeted&#xD;
                  therapy for metastatic castration-sensitive prostate cancer or CRPC&#xD;
&#xD;
               -  No prior cytotoxic chemotherapy in the metastatic CRPC setting&#xD;
&#xD;
                    -  For participants who received cytotoxic chemotherapy in CSPC, at least 6&#xD;
                       months must have elapsed between last dose of chemotherapy and start of&#xD;
                       study treatment&#xD;
&#xD;
                    -  No more than 1 prior line of cytotoxic chemotherapy for CSPC&#xD;
&#xD;
               -  Participants with measurable and non-measurable disease are eligible if the&#xD;
                  following criteria are met:&#xD;
&#xD;
                    -  A minimum starting PSA level â‰¥1.0 ng/mL&#xD;
&#xD;
                    -  Participants with measurable soft tissue disease must have evidence of&#xD;
                       measurable soft tissue disease according to PCWG3 criteria.&#xD;
&#xD;
                    -  Participants with non-measurable disease must have documented rising PSA&#xD;
                       levels or appearance of new lesion according to PCWG3&#xD;
&#xD;
               -  Participants with known breast cancer gene (BRCA) mutations are excluded&#xD;
&#xD;
               -  No prior radioscope therapy or radiotherapy to â‰¥30% of bone marrow&#xD;
&#xD;
          -  Cohort 8: Melanoma&#xD;
&#xD;
               -  Must have histologically or cytotoxically confirmed cutaneous malignant melanoma&#xD;
&#xD;
                    -  Participants with mucosal, acral, or uveal melanoma are excluded&#xD;
&#xD;
               -  Must have locally advanced unresectable or metastatic stage disease&#xD;
&#xD;
               -  Must have measurable disease&#xD;
&#xD;
               -  Must have progressive disease following anti-PD(L)1 therapy&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active concurrent malignancy or a previous malignancy within the past 3 years&#xD;
&#xD;
          -  Any anticancer therapy within 3 weeks of starting study treatment. Participants who&#xD;
             are/were on adjuvant hormonal therapy for the treatment of malignancies with&#xD;
             negligible risk of metastases are eligible.&#xD;
&#xD;
          -  Known active central nervous system lesions&#xD;
&#xD;
          -  Active viral, bacterial, or fungal infection requiring systemic treatment within 7&#xD;
             days prior to the first dose of LV&#xD;
&#xD;
          -  Any ongoing clinically significant toxicity associated with prior treatment (Grade 2&#xD;
             or higher)&#xD;
&#xD;
          -  Ongoing sensory or motor neuropathy of Grade â‰¥2&#xD;
&#xD;
          -  Documented history of a cerebral vascular event (stroke or transient ischemic attack),&#xD;
             unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive&#xD;
             heart failure&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study treatment&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of the planned start of study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zejing Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ironwood Cancer &amp; Research Centers - Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Gillam</last_name>
      <phone>480-314-6685</phone>
    </contact>
    <investigator>
      <last_name>Sujith R Kalmadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adventist Health White Memorial</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Montero</last_name>
      <phone>323-268-5000</phone>
      <email>monterhe@ah.org</email>
    </contact>
    <investigator>
      <last_name>Raymundo Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Heritage Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Lund</last_name>
      <phone>707-521-3814</phone>
      <email>Teresa.lund@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Ian C Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tambree Chapman</last_name>
      <phone>860-886-8362</phone>
      <email>tchapman@echoct.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare USA</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Novella</last_name>
      <phone>239-938-9315</phone>
      <email>rachel.novella@21co.com</email>
    </contact>
    <investigator>
      <last_name>Troy H Guthrie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Fogg-Smith</last_name>
      <phone>407-303-2523</phone>
      <email>Stacy.Fogg-Smith@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Tarek Mekhail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
      <phone>888-737-7408</phone>
      <email>gscott@iacthealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Tenetta Holt</last_name>
      <phone>706-321-0495</phone>
      <email>tholt@iacthealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Clark</last_name>
      <phone>312-695-8070</phone>
    </contact>
    <investigator>
      <last_name>Mary F Mulcahy</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria M Villaflor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelley Seabolt</last_name>
      <phone>260-969-7818</phone>
    </contact>
    <investigator>
      <last_name>Sunil Babu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Alimurong</last_name>
      <phone>410-328-2703</phone>
      <email>joann.alimurong@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Ranee Mehra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Schroeder</last_name>
      <phone>734-647-9437</phone>
      <email>morrowam@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Swiecicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Lacy</last_name>
      <phone>952-993-1516</phone>
    </contact>
    <investigator>
      <last_name>Daniel M Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vogelzang</last_name>
      <phone>702-952-3400</phone>
    </contact>
    <investigator>
      <last_name>Fadi S Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Vogelzang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital, The / Luckow Pavilion</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taja Fergurson</last_name>
      <phone>201-389-0198</phone>
      <email>TFergus2@Valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eli Kirshner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sardar Z Imam</last_name>
      <phone>505-564-6850</phone>
    </contact>
    <investigator>
      <last_name>Sardar Z Imam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Shah</last_name>
      <phone>646-962-6200</phone>
      <email>mas9313@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Manish Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-7263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Fidnarick</last_name>
      <phone>631-444-3577</phone>
      <email>Cara.Fidnarick@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Amna Sher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth of the Carolinas</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Williams</last_name>
      <phone>910-715-1922</phone>
      <email>jcwilliams@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles Kuzma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lopez</last_name>
      <phone>503-215-5696</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel E Sanborn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital / Bon Secours - South Carolina</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Smith</last_name>
      <phone>864-603-6220</phone>
      <email>Gina_Smith@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert D Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Oncology and Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Metcalf</last_name>
      <phone>423-778-2982</phone>
      <email>Jill.Metcalf@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Robert (Matt) Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Salas</last_name>
      <phone>806-725-8068</phone>
      <email>ssalas@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Isaac Tafur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health East Texas Hope Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Loredo</last_name>
      <phone>903-592-6152</phone>
      <phone_ext>286</phone_ext>
      <email>Grace.Loredo@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsey Deverman</last_name>
      <phone>608-263-1836</phone>
      <email>lyndsey.deverman@wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laboratory Inbox</last_name>
      <phone>608-263-5369</phone>
      <email>3plab@lists.medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Justine Y Bruce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>Other</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christos S Karapetis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Other</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Abhishek Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peninsula and South East Oncology</name>
      <address>
        <city>Frankston</city>
        <state>Other</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7460</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Vinod Ganju</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Coast Local Health District (Gosford and Wyong Hospitals)</name>
      <address>
        <city>Gosford</city>
        <state>Other</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Matthew Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Other</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Louise Nott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabrini</name>
      <address>
        <city>Malvern</city>
        <state>Other</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Gary Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>Other</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7460</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Joshua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Other</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Stefania Salvagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <state>Other</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Antonuzzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL 3 Genovese Villa Scassi Hospital</name>
      <address>
        <city>Genova</city>
        <state>Other</state>
        <zip>16125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Manlio Mencoboni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Luca Hospital</name>
      <address>
        <city>Lucca</city>
        <state>Other</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Editta Baldini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Other</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Giuseppe Curigliano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niguarda Ca' Granda Hospital</name>
      <address>
        <city>Milan</city>
        <state>Other</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Salvatore Siena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Gerardo di Monza Hospital</name>
      <address>
        <city>Monza</city>
        <state>Other</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Diego Cortinovis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Other</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Paolo Ascierto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <state>Other</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Antonia Strippoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOUS Policlininico Le Scotte</name>
      <address>
        <city>Siena</city>
        <state>Other</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Michele Maio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Other</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sung Yong Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Other</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>In-Jae Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Other</state>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Seok Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Do-Youn Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jae Yong Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Jeeyun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>07671</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7460</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jin-Soo Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>152-703/08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Suwon-si</city>
        <state>Other</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Byoung Young Shim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Other</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hyun Woo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Other</state>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Tsung-Ying Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <state>Other</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Other</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Chia-Chi Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Other</state>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Po-Li Wei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Other</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Jeff Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>425-527-4000</phone>
    </contact>
    <investigator>
      <last_name>Ian Chau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>WC1E6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>John Bridgewater</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Khurum Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>Other</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
    </contact>
    <investigator>
      <last_name>Matthew Krebs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Other</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>425-527-4000</phone>
    </contact>
    <investigator>
      <last_name>Ian Chau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>NSCLC-squamous</keyword>
  <keyword>NSCLC-nonsquamous</keyword>
  <keyword>HNSCC</keyword>
  <keyword>GEJ adenocarcinoma</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

